|
|
|
| Value of NEDD9 for Diagnosis and Prediction of Prognosis in Pancreatic Cancer |
| XU Yu, HE Hai-tao, WEI Zhi-li, et al |
| The Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine,Xixian New District Shaanxi 712000 |
|
|
|
|
Abstract 【Objective】 To investigate the value of neuronal expression developmentally downregulated gene 9(NEDD9) for diagnosis and prediction of prognosis in pancreatic cancer. 【Methods】A total of 80 patients with pancreatic cancer,who were treated for the first time in our hospital and confirmed by rapid pathological biopsy,were enrolled in the study. The pancreatic cancer tissues and normal tissues adjacent to the cancer were collected. The expression of NEDD9 in pancreatic cancer tissues and normal tissues was detected by both immunohistochemistry and qPCR. The relationship between NEDD9 and clinical features of pancreatic cancer was analyzed. And the effect of NDEE9 on clinical prognosis of patients with pancreatic cancer was discussed. 【Results】Compared to normal tissues,the expression rate of NEDD9 in pancreatic cancer tissues was significantly higher (71.25% vs 51.25%,P<0.05); And the level of NEDD9 mRNA was also significantly higher than that of normal tissue (0.92±0.17) vs (0.33±0.09),P<0.05). The clinical stage (stage Ⅰ-Ⅱ) and degree of differentiation (high differentiation) in patients with low expression of NEDD9 were significantly better than those who had higher expression level of NEDD9.Follow-up results showed that the expression level of NEDD9 in patients with poor prognosis (1.21±0.31) was significantly higher than that in the group with good prognosis (0.73±0.25) (P<0.05).Binary logistic regression analysis found that high expression of NEDD9 was an independent risk factor for negative prognosis of pancreatic cancer,and its odds ratio was 2.18 (1.16-4.01).【Conclusion】 NEDD9 was highly expressed in pancreatic cancer tissues and it was associated with clinical stage and pancreatic cancer grading. The high expression of NEDD9 was an independent risk factor for negative prognosis in patients with pancreatic cancer.
|
|
Received: 10 May 2022
|
|
|
|
|
|
[1] 张程,孟迪,张禀业,等. 外泌体在胰腺癌诊断中的作用[J].临床肝胆病杂志,2019,35(5):1165-1167.
[2] 沈力,征锦. 定量影像技术在胰腺癌诊断中的应用[J].中国基层医药,2019,26(1):123-128.
[3] 候惠,刘惠敏,古再丽阿依?阿不力孜,等. 肿瘤标志物CEA、CA724、CA199在评估胰腺癌治疗预后中的应用价值[J].消化肿瘤杂志(电子版),2019,11(3):267-271.
[4] 吴铁龙,薛丽莉,戴圆圆,等. 神经前体细胞表达下调蛋白9在胰腺癌组织中的表达及临床意义[J].临床肝胆病杂志,2017,33(1):130-132.
[5] 杨秀燕,刘海芳. NEDD9在胰腺癌组织中的表达及与临床病理的相关性分析[J].中华胰腺病杂志,2019,19(2):134-136.
[6] ZHANG S S,WU L H,LIU Q,et al. Elevated expression of NEDD9 is associated with metastatic activity in gastric cancer [J].Onco Targets Ther,2015,8(4):633-640.
[7] LU P,WANG Z P,DANG Z,et al. Expression of NEDD9 in hepatocellular carcinoma and its clinical significance [J].Oncol Rep,2015,33(5):2375-2383.
[8] SIMA N,CHENG X D,YE F,et al. The overexpression of scaffolding protein NEDD9 promotes migration and invasion in cervical cancer via tyrosine phosphorylated FAK and SRC [J].PLoS One,2013,8(9):e74594.
[9] 李豪杰,徐庭凯,王连迪. NEDD9 表达下调对结肠癌生物学行为的影响[J].胃肠病学,2019,24(8):480-485.
[10] 常静侠. NEDD9肺腺癌中的表达及其基因沉默对肺腺癌A549细胞生物学行为的影响[D]. 郑州:郑州大学,2013. |
|
|
|
2023, Vol. 40 
